After sustained pressure over the past few quarters, things appear set to gather pace in the US for Lupin Ltd., with its base business products reporting gains and impending launches promising further momentum, though the firm ended Q3 with a loss post exceptional items.
Some of the US bounce back, Lupin’s management indicated, has been aided by the moderation in pricing pressures and opportunities...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
